Takeda Pharmaceutical Receives Exclusive License for LG474, Promising Drug for Treatment of Cardiovascular Disease.Tokyo, Japan, Mar 2, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takeda Pharmaceutical announced on March 2 that it received the exclusive right to use LG474, a substance discovered through its collaboration Working together on a project. See collaborative software. with Lexicon Genetics genetics, scientific study of the mechanism of heredity. While Gregor Mendel first presented his findings on the statistical laws governing the transmission of certain traits from generation to generation in 1856, it was not until the discovery and detailed study of in the US. In July 2004, the two companies entered into a partnership under which Takeda can select and purchase promising targets for anti-hypertension medicine that were discovered in Lexicon's Genome genome: see genetics. genome all the genetic content contained within an organism. An organism's genome is made up of molecules of deoxyribonucleic acid (DNA) that form long strands that are tightly wound into chromosomes, which are found in the 5000 program. Takeda made a milestone payment of US $12 million for the newly-selected target LG474. Furthermore, Lexicon Genetics will receive milestone payments and royalties from sales from Takeda. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion